Table 1 Comparison of baseline patients and disease characteristics between TSC groups and non-TSC groups
Characteristics | Total (n = 381) | TSC (n = 164) | Non-TSC (n = 217) | p-value |
|---|---|---|---|---|
Age (years), median (IQR) | 37 (29, 49) | 35 (28.75, 47) | 38 (29, 50) | 0.175 |
Female Sex, n (%) | 106 (27.8%) | 58 (35.4%) | 48 (22.1%) | 0.004 |
Age at onset of psoriasis (year), median (IQR) | 27 (20, 37) | 26 (18.75, 34) | 27 (21, 39) | 0.064 |
Duration of psoriasis (year), median (IQR) | 7 (2, 14) | 8 (3, 15) | 7 (2, 14) | 0.266 |
Bodyweight (kg), median (IQR) | 70 (61, 80) | 67.75 (58, 78.25) | 72 (64, 81) | 0.014 |
Baseline PASI score, median (IQR) | 15 (10.3, 21.6) | 14.5 (10.15, 19.15) | 15.28 (10.4, 25.2) | 0.079 |
Baseline BSA score, median (IQR) | 20 (10, 35.6) | 19.8 (10.38, 34.48) | 21 (10, 40) | 0.244 |
Baseline DLQI score, median (IQR) | 12 (7, 18) | 10 (6.75, 16.25) | 12 (7, 18) | 0.165 |
Comorbidities | ||||
 Hypertension, n (%) | 45 (11.8%) | 17 (10.4%) | 28 (12.9%) | 0.447 |
 Hyperlipidemia, n (%) | 77 (20.2%) | 27 (16.5%) | 50 (23.0%) | 0.113 |
 Diabetes mellitus, n (%) | 22 (5.8%) | 9 (5.5%) | 13 (6.0%) | 0.835 |
 Obesity, n (%) | 66 (17.3%) | 23 (14.0%) | 43 (19.8%) | 0.139 |
Prior psoriasis treatments | ||||
 Previous systemic non-biologic treatments, n(%) | 215 (56.4%) | 92 (56.1%) | 123 (56.7%) | 0.909 |
 Previous phototherapy, n (%) | 71 (18.6%) | 38 (23.2%) | 33 (15.2%) | 0.048 |
 Previous biologic treatments, n (%) | 35 (9.2%) | 8 (4.9%) | 27 (12.4%) | 0.011 |
Psoriasis involvement | ||||
 Joints affected, n (%) | 144 (37.8%) | 47 (28.7%) | 97 (44.7%) | 0.001 |
 Nails affected, n (%) | 125 (32.8%) | 41 (25.0%) | 84 (38.7%) | 0.005 |
 Scalp affected, n (%) | 322 (84.5%) | 137 (83.5%) | 185 (85.3%) | 0.646 |
 Palmoplantar area affected, n (%) | 102 (26.8%) | 39 (23.8%) | 63 (29.0%) | 0.252 |
 Genital area affected, n (%) | 44 (11.5%) | 11 (6.7%) | 33 (15.2%) | 0.010 |